Translational Development Acquisition Corp.
TDACW- Exchange
- Nasdaq
- Industry
- Blank Checks
- SEC CIK
- 0001926599
No open-market purchases or sales by Translational Development Acquisition Corp. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $10.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Translational Development Acquisition Corp. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Translational Development Acquisition Corp., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hoffman Michael B | Chairman and CEO | – | May 29, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 29, 2026 (view filing) | May 27 | 2 days | Hoffman Michael BChairman and CEO | PPurchaseClass A ordinary shares | +53.4K | $0.79 | +$42.2K | –53.4K after | Derivative |